STOCKS TELEGRAPH

Tag: DBV stock

  • DBV Technologies (DBVT) Stock Climbs Following Strategic Equity Raise

    DBV Technologies (DBVT) Stock Climbs Following Strategic Equity Raise

    The stock market saw a spectacular increase in DBV Technologies S.A. (NASDAQ: DBVT) shares, which as of the latest check were up 60.34% to $6.27. Following the company’s announcement of a sizable funding deal intended to support its development plans, the stock value increased significantly.

    The Multi-Million Finance Plan

    DBV Technologies has negotiated a $306.9 million (€284.5 million) finance deal. At closure, DBVT anticipates gross proceeds of $125.5 million (€116.3 million). Additionally, if all related warrants are exercised, subject to certain restrictions, a total of up to $181.4 million (€168.2 million) might be raised.

    The accomplishment of the primary outcome in the current VITESSE Phase 3 research is a crucial catalyst for warrant acceleration. The majority of the recently obtained money will go toward general business operations and working capital.

    They will also be used to advance the Viaskin Peanut program, draft and submit a possible Biologics License Application (BLA), and, subject to regulatory approval, help with the possible commercial launch of Viaskin Peanut in the United States.

    However, it is anticipated that the financing structure will dilute current shareholders by 22.4%; if all warrants are exercised, the maximum possible dilution on a non-diluted basis may reach 73.7%.

    Key Investors Behind the Transaction

    Several well-known institutional investors supported the fundraising round, including Yiheng Capital, Bpifrance Participations, Octagon Capital, Vivo Capital, Janus Henderson Investors, Surveyor Capital (a Citadel subsidiary), MPM BioImpact, and Adage Capital Management LP. Together with other healthcare-focused funds, these investors have shown confidence in DBV Technologies’ potential for long-term success.

    Moving Forward with Commercialization and FDA Submission

    The investment comes after DBV Technologies recently partnered with the FDA to harmonize safety exposure data for a BLA filing for its Viaskin Peanut patch for kids ages 4–7. With this funding, the business may move more quickly toward becoming a commercial entity, finishing out the required research and being ready to submit to the government.

    The funds will also help DBVT get ready for the possible introduction of Viaskin Peanut in toddlers ages 1-3 and kids ages 4-6, subject to FDA clearance. The funding agreement strengthens DBV Technologies’ strategic positioning and dedication to treating pediatric peanut allergy with cutting-edge therapeutic approaches as it advances.

  • Early Morning Vibes: Top 4 Stocks To Watch Right Now

    Early Morning Vibes: Top 4 Stocks To Watch Right Now

    For Martin Luther King Day, the U.S. treasuries were closed yesterday. In the meantime, on Wednesday, the Americans are waiting for the unveiling of Joe Biden. In the run-up to that time, a $1900 billion corona support plan was already revealed. Janet Yellen, Minister of Economy, also accepts. The former Fed Chairman suggests that a massive boost can be used to generate the existing low-interest rates.

    The future of New York is now pointed to a higher start. The S&P future is 0.48% higher and the Nasdaq trading is even 0.80% higher. The annual findings of Bank of America and Goldman Sachs will be revealed this afternoon at 1 p.m. It’s the turn of Netflix after the closure at 10:00 PM. In the fourth quarter of 2020, JPMorgan Chase analysts plan to welcome 6 million users on the subscription site.

    Today Top Movers

    DBV Technologies (DBVT), a biotechnology company, rose about 37.99% ‎at $7.81 in pre-market trading Tuesday after it declared the receipts of written responses from the FDA to the question asked for the ‎Type A request the company submitted in Oct 2020.

    Gevo Inc (GEVO) share price climbed 39.22% to $8.91 during early morning ‎trading session on Tuesday.‎ The company will participate in Water Tower Research Fireside Chat Series on Thursday, January 21, 2021 at 3:00 pm EST.

    Nio Inc (NIO) stock escalated 4.37% at $58.73 in the pre-‎market trading today after declaring the closing of US$1.5 billion convertible senior notes.

    Castor Maritime Inc (CTRM) hiked over 8.10% at $0.36 in pre-market ‎trading on Tuesday.‎

    Top Upgrades & Downgrades

    KeyBanc turned bullish on Facebook Inc. (FB), upgrading the stock to “Overweight” and assigning a $345.0 price target, representing a potential upside of 29.3% from Friday’s close.

    Darden Restaurants Inc. (DRI) has won the favor of Morgan Stanley’s equity research team. The firm upgraded the shares from Equal-Weight to Overweight and moved their price target to $142.0, suggesting 17.23% additional upside for the stock. 

    Arch Capital Group Ltd. (ACGL) received an upgrade from analysts at JMP Securities. They changed their rating on ACGL to Market Outperform from Market Perform in a recently issued research note. 

    Earlier Tuesday BofA reduced its rating on Acadia Realty Trust (NYSE: AKR) stock to Neutral from Buy and assigned the price target to $17.50. 

    BofA analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Premier Inc (NASDAQ: PINC) has been changed to Underperform from Buy and the new price target is set at $36. 

    Analysts at BofA downgraded Cerner Corporation (NASDAQ: CERN)’s stock to Underperform from Buy Tuesday.

    Latest Insider Activity

    TransEnterix Inc. (TRXC) Director Milne David Bruce announced the sale of shares taking place on Jan 15 at $2.10 for some 147,058 shares. The total came to more than $0.31 million.

    Inovio Pharmaceuticals Inc. (INO) CFO KIES PETER sold on Jan 15 a total of 119,290 shares at $10.02 on average. The insider’s sale generated proceeds of almost $0.3 million. 

    Amicus Therapeutics Inc. (FOLD) Director WHITMAN BURKE W declared the purchase of shares taking place on Jan 04 at $23.17 for some 1,500 shares. The transaction amount was around $34755. 

    C.H. Robinson Worldwide Inc. (CHRW) Director SHORT BRIAN bought on Jan 04 a total 21,843 shares at $93.58 on average. The purchase cost the insider an estimated $5,159.

    Important Earnings

    Top US earnings releases scheduled for today include Bank of America Corporation (NYSE: BAC). It will announce its Dec 2020 financial results. The company is expected to report earnings of $0.55 per share from revenues of $20.68B in the three-month period.

    Analysts expect Halliburton Company (NYSE: HAL) to report a net income (adjusted) of $0.15 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $3.21B.

    Netflix Inc. (NFLX), due to announce earnings after the market closes today, is expected to report earnings of $1.39 per share from revenues of $6.63B recently concluded three-month period.